fbpx
Menu

FOR IMMEDIATE RELEASE: CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER AND FIRST NINE MONTHS 2018 FINANCIAL AND BUSINESS RESULTS

Share

Key new hires include Chief Financial Officer and President, CASI China as CASI prepares for global commercialization efforts 

Acquired U.S. FDA-approved abbreviated new drug application (ANDA) from Laurus Labs Limited 

China FDA (CFDA) import drug registration priority review of EVOMELA in progress and preparations continue for commercial launch in China 
CFDA review in progress for MARQIBO and ZEVALIN,
ROCKVILLE, Md. (November 14, 2018) CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innovative therapeutics to patients in the U.S., China and throughout the world, today reported financial results for the third quarter and nine months ended September 30, 2018 and provided a review of recent accomplishments and anticipated upcoming milestones. Ken K. Ren, Ph.D., CASIs Chief Executive Officer, commented, CASI made substantial progress in the third quarter. We continue working with relevant regulatory authorities and our strategic partners in the U.S. and in China to advance EVOMELA, MARQIBO, and ZEVALIN closer to the finish line in terms of CFDA approval and are making solid progress on all fronts. Our recent appointments of George Chi as Chief Financial Officer and Larry Zhang as President of CASIs Beijing operations further underscore our commitment to bringing high-quality, cost-effective pharmaceutical products and innovative therapeutics to the market, and enables us to significantly ramp up our commercial preparatory activities. We recently acquired a U.S. FDA-approved ANDA for HBV from Laurus Labs Limited and continue to pursue opportunities to further augment our pipeline in conjunction with our broader mission. …

[Read on via official release]

Source: US SEC
View full document:
8-K_for_CASI_Pharmaceuticals_Inc_8-K-11-14-2018